NEW YORK, June 14, 2017 /PRNewswire/ --
DailyStockTracker.com has issued research reports on the following four equities:Rexahn Pharmaceuticals Inc. (NYSEMKT: RNN), Novavax Inc. (NASDAQ: NVAX), and Protalix BioTherapeutics Inc. (NYSEMKT: PLX). These stocks are part of the Biotechnology industry, which consists of companies engaged in the research and development of new
Rockville, Maryland headquartered Rexahn Pharmaceuticals Inc.'s shares gained 0.64%, closing Tuesday's trading session at $3.15. The stock recorded a trading volume of 425,613 shares. Shares of the Company have surged 121.99% since the start of this year. The stock is trading 14.82% above its 200-day moving average. Additionally, shares of Rexahn Pharma, which discovers, develops, and commercializes treatments for cancer, have a Relative Strength Index (RSI) of 33.41.
On June 04th, 2017, Rexahn Pharma announced an interim update on the safety and efficacy of RX-3117 in an ongoing Phase-IIa clinical trial in metastatic bladder cancer at the American Society for Clinical Oncology 2017 Annual Meeting. The study achieved the Company's predefined criteria for efficacy in metastatic bladder cancer. Twenty percent of patients showed progression free survival of greater than six months, and there was tumor reduction in some patients. See our free and comprehensive research report on RNN at:
On Tuesday, shares in Gaithersburg, Maryland headquartered Novavax Inc. recorded a trading volume of 2.33 million shares. The stock ended the day flat at $1.06. The Company's shares have advanced 6.00% in the past month. The stock is trading above its 50-day moving average by 12.11%. Furthermore, shares of Novavax, which focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, have an RSI of 56.58.
On June 07th, 2017, Novavax announced that data from the second of two Phase-2 trials of its RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in women of childbearing age have been published in the journal, Vaccine. The Company previously announced top-line results from this trial in April 2014. It is developing the RSV F Vaccine with the goal of protecting infants from RSV disease. NVAX free research report is just a click away at:
Karmiel, Israel-based Protalix BioTherapeutics Inc.'s stock finished the day 3.70% higher at $0.84 with a total trading volume of 798,042 shares. The Company's shares have advanced 88.76% on an YTD basis. The stock is trading above its 200-day moving average by 14.29%. Additionally, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of 41.67.
On June 07th, 2017, Protalix BioTherapeutics announced that phase-II trial results, including new clinical data, for alidornase alfa (PRX-110) for the treatment of Cystic Fibrosis (CF) will be the subject of an oral presentation at the 40th European Cystic Fibrosis Society Conference in Seville, Spain. Alidornase alfa is a plant cell-expressed, chemically-modified recombinant DNase I enzyme resistant to inhibition by actin, which the Company has specifically designed to enhance the enzyme's efficacy in CF patients. Register for free on DailyStockTracker.com and download the latest research report on PLX at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All